Regulation of LPL in patients with the metabolic syndrome

• Conditions: fat in blood; high cholesterol; 10011082; 10013317

• Registration Number: NL-OMON34217
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

Patient with metabolic syndrome will have to meet at least three of the following criteria (HTG will be a mandatory criteria).
o Central obesity; WC > 94 cm in male and > 80 cm in female
o Elevated plasma triglycerides 2.0-6.0 mmol/L
o Fasting plasma glucose (FPG) < 5.6 mmol/L

Exclusion Criteria

* BMI >32
* Cardiovascular disease
* Current use of the following medications: Heparin, or other blood diluting medication
* Hepatic dysfunction
* End stage renal disease
* History of bleeding or recent surgical intervention

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Differences between cases and controls for:<br /><br>Plasma cholesterol, triglycerides, LDLc, HDLc, apoAI, apoB, apoCII, apoE,<br /><br>apoCIII, ApoAV and ANGPLT 3 and 4<br /><br>mRNA expression and protein concentration of LPL, GPIHBP1 and ANGPTL4 in<br /><br>adipose tissue<br /><br>mRNA expression and protein concentration of LPL, GPIHBP1 and ANGPTL4 in muscle<br /><br>tissue<br /><br>Histological examination of adipose tissue using antibodies against LPL,<br /><br>GPIHBP1 and ANGPTL4.<br /><br>Histological examination of muscle tissue using antibodies against LPL, GPIHBP1<br /><br>and ANGPTL4</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>not applicable</p><br>